Q1 2026 delivered three simultaneous inflection events in longevity and human performance: the FDA's first-ever clearance of an epigenetic reprogramming therapy for human trials, Eli Lilly achieving $8.66B in a single quarter on GLP-1, and $3.74B in longevity biotech financing · 56% above the prior year. This report maps each layer of the convergence with primary-source data and three decisions that cannot wait for Q2.